Skip to content
Medical Health Aged Care

Medical Thought Leaders to Convene in Ukraine for Collaborative Summit

The JANZ Corporation 2 mins read

COLUMBUS, OHIO / ACCESSWIRE / July 18, 2023 / An International Healthcare Summit has been scheduled in Kyiv, Ukraine for Nov. 7-9, 2023. August Mission, a humanitarian non-profit agency, and JANZ Corporation, a global medical equipment supplier, will be hosting the Summit through the approval of the Kyiv Regional State and Military Administration. This three-day Summit will feature discussions on medical innovation, education, and medical expertise, in various fields and modalities with an emphasis on military-related injuries and rehabilitation. It will bring together top officials from Ukraine, including representatives of the Cabinet of Ministers, heads of regional administrations, international organizations, Ukrainian medical institutions/doctors, and industry experts to exchange knowledge and ideas with the aim of shaping the future of healthcare and ensure a higher quality of life for all.

Photo for release
Frontline soldier on one side and a doctor on the other. Summit logo in top center

Discussion Tracks will include Battlefield Trauma (Hemorrhagic Shock, Traumatic BrainInjuries, Transport and etc.), Hospital Services (Surgical Procedures, Pharmaceuticals, and Medical Equipment) and Rehabilitation (Prosthetics and Mental Health), Panels of experts will be scheduled to share ideas and discuss "Lessons Learned" in a wartime environment. Time will also be allotted during the three days to visit local hospitals, rehabilitation centers and to meet with healthcare-related dignitaries.

To learn more and/or register for the International Healthcare Summit-Ukraine 2023, please visit our website at www.internationalhealthcaresummit.org

August Mission is driven by a profound commitment to alleviate human suffering and address the multifaceted challenges related to humanitarian support, recovery, and resettlement. With a focus on displaced persons, persecuted groups/individuals, and marginalized populations, August Mission strives to develop innovative solutions that can make a meaningful difference in the lives of those affected. Website: https://augustmission.org

JANZ Corporation is a healthcare-centric Service-Disabled Veteran Owned Small Business (SDVOSB) dedicated to providing exceptional medical equipment, supplies, and therapy services to all levels of the U.S. Government. With a strong commitment to serving the needs of the military community, JANZ Corporation has become a trusted partner in delivering essential healthcare solutions. Website: https://janzcorp.com

Contact Information

Makenzie Holland
Marketing Manager, JANZ Corporation
[email protected]
6147597700

Claudia VanHuffel
[email protected]
6147597700

SOURCE: JANZ Corporation

.


View source version on accesswire.com:
https://www.accesswire.com/768167/Medical-Thought-Leaders-to-Convene-in-Ukraine-for-Collaborative-Summit

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.